FDA Approved: BESREMI — Supplemental Application (PharmaEssentia USA)

View source ↗

Summary

The FDA approved a supplemental application for BESREMI (ropeginterferon alfa-2b) submitted by PharmaEssentia USA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• BESREMI (ropeginterferon alfa-2b)

Snippet

SUPPL AP for BESREMI (ROPEGINTERFERON ALFA-2B)